Total Payments
$4,204
2024 Payments
$157.81
Companies
26
Transactions
241
Medicare Patients
1,576
Medicare Billing
$199,237
Payment Breakdown by Category
Food & Beverage$4,204 (100.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $4,204 | 241 | 100.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ABBVIE INC. | $1,052 | 83 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $918.38 | 17 | $0 (2023) |
| Allergan, Inc. | $711.81 | 48 | $0 (2020) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $307.86 | 19 | $0 (2024) |
| PFIZER INC. | $134.81 | 5 | $0 (2023) |
| E.R. Squibb & Sons, L.L.C. | $114.95 | 6 | $0 (2019) |
| Bayer Healthcare Pharmaceuticals Inc. | $110.10 | 7 | $0 (2023) |
| Lilly USA, LLC | $97.85 | 7 | $0 (2022) |
| Abbott Laboratories | $95.28 | 2 | $0 (2023) |
| Takeda Pharmaceuticals U.S.A., Inc. | $86.88 | 9 | $0 (2021) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $157.81 | 10 | Boehringer Ingelheim Pharmaceuticals, Inc. ($107.26) |
| 2023 | $558.07 | 28 | ABBVIE INC. ($239.68) |
| 2022 | $716.11 | 45 | ABBVIE INC. ($324.59) |
| 2021 | $1,147 | 60 | AstraZeneca Pharmaceuticals LP ($420.26) |
| 2020 | $398.06 | 35 | Allergan, Inc. ($140.15) |
| 2019 | $537.67 | 19 | Allergan Inc. ($318.53) |
| 2018 | $299.59 | 20 | Allergan Inc. ($115.16) |
| 2017 | $389.43 | 24 | Allergan Inc. ($137.97) |
All Payment Transactions
241 individual payment records from CMS Open Payments — Page 1 of 10
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 10/23/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $17.75 | General |
| Category: DIABETES | ||||||
| 09/25/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $13.92 | General |
| Category: DIABETES | ||||||
| 08/22/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $16.66 | General |
| Category: DIABETES | ||||||
| 07/17/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $14.67 | General |
| Category: DIABETES | ||||||
| 06/20/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $15.83 | General |
| Category: DIABETES | ||||||
| 05/16/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $13.80 | General |
| Category: DIABETES | ||||||
| 04/11/2024 | ABBVIE INC. | UBRELVY (Drug) | Food and Beverage | In-kind items and services | $17.74 | General |
| Category: NEUROSCIENCE | ||||||
| 04/05/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $18.67 | General |
| Category: NEUROSCIENCE | ||||||
| 03/26/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $14.63 | General |
| Category: DIABETES | ||||||
| 01/19/2024 | ABBVIE INC. | QULIPTA (Drug), UBRELVY | Food and Beverage | In-kind items and services | $14.14 | General |
| Category: NEUROSCIENCE | ||||||
| 12/11/2023 | ABBVIE INC. | QULIPTA (Drug), UBRELVY | Food and Beverage | In-kind items and services | $4.68 | General |
| Category: NEUROSCIENCE | ||||||
| 12/01/2023 | ABBVIE INC. | QULIPTA (Drug), UBRELVY | Food and Beverage | In-kind items and services | $21.06 | General |
| Category: NEUROSCIENCE | ||||||
| 11/27/2023 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $21.31 | General |
| Category: DIABETES | ||||||
| 11/20/2023 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $15.74 | General |
| Category: NEUROSCIENCE | ||||||
| 11/13/2023 | ABBVIE INC. | QULIPTA (Drug), UBRELVY | Food and Beverage | In-kind items and services | $6.89 | General |
| Category: NEUROSCIENCE | ||||||
| 11/13/2023 | ABBVIE INC. | QULIPTA (Drug), UBRELVY | Food and Beverage | In-kind items and services | $3.89 | General |
| Category: NEUROSCIENCE | ||||||
| 10/25/2023 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $121.00 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 10/20/2023 | ABBVIE INC. | UBRELVY (Drug) | Food and Beverage | In-kind items and services | $15.69 | General |
| Category: NEUROSCIENCE | ||||||
| 08/16/2023 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $17.04 | General |
| Category: NEUROSCIENCE | ||||||
| 08/14/2023 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $18.51 | General |
| 08/11/2023 | ABBVIE INC. | UBRELVY (Drug) | Food and Beverage | In-kind items and services | $14.12 | General |
| Category: NEUROSCIENCE | ||||||
| 08/09/2023 | PFIZER INC. | PAXLOVID (Drug) | Food and Beverage | In-kind items and services | $13.85 | General |
| Category: INFECTIOUS DISEASES | ||||||
| 06/30/2023 | Abbott Laboratories | FREESTYLE LIBRE 3 (Device) | Food and Beverage | In-kind items and services | $80.28 | General |
| Category: Diabetes Care | ||||||
| 06/30/2023 | Abbott Laboratories | FREESTYLE LIBRE 3 (Device) | Food and Beverage | In-kind items and services | $15.00 | General |
| Category: Diabetes Care | ||||||
| 06/23/2023 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $11.08 | General |
| Category: NEUROSCIENCE | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 3 | 284 | 547 | $75,180 | $39,844 |
| 2022 | 3 | 326 | 664 | $90,160 | $48,131 |
| 2021 | 4 | 377 | 798 | $105,010 | $59,328 |
| 2020 | 9 | 589 | 1,069 | $99,751 | $51,934 |
Total Patients
1,576
Total Services
3,078
Medicare Billing
$199,237
Procedure Codes
19
All Medicare Procedures & Services
19 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 195 | 438 | $61,320 | $31,465 | 51.3% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 33 | 37 | $6,660 | $4,282 | 64.3% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 56 | 72 | $7,200 | $4,097 | 56.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 241 | 548 | $76,720 | $40,490 | 52.8% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 64 | 93 | $9,300 | $4,590 | 49.4% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 21 | 23 | $4,140 | $3,050 | 73.7% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 269 | 640 | $86,450 | $48,122 | 55.7% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 66 | 89 | $8,640 | $4,891 | 56.6% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 29 | 35 | $6,180 | $4,475 | 72.4% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 13 | 34 | $3,740 | $1,840 | 49.2% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 287 | 678 | $74,580 | $41,040 | 55.0% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 70 | 96 | $7,680 | $3,726 | 48.5% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Office | 2020 | 27 | 30 | $4,500 | $3,161 | 70.2% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 18 | 35 | $3,850 | $1,612 | 41.9% |
| 99204 | New patient office or other outpatient visit, typically 45 minutes | Office | 2020 | 11 | 11 | $1,760 | $923.12 | 52.4% |
| 99239 | Hospital discharge day management, more than 30 minutes | Facility | 2020 | 11 | 12 | $2,676 | $771.48 | 28.8% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2020 | 135 | 176 | $3,520 | $523.56 | 14.9% |
| 69209 | Removal of impacted ear wax by washing | Office | 2020 | 11 | 11 | $825.00 | $107.95 | 13.1% |
| 81002 | Urinalysis, manual test | Office | 2020 | 19 | 20 | $360.00 | $68.69 | 19.1% |
About Dr. Gregory Quin, MD
Dr. Gregory Quin, MD is a Legal Medicine healthcare provider based in Peru, Indiana. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/28/2005. The National Provider Identifier (NPI) number assigned to this provider is 1548260714.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Gregory Quin, MD has received a total of $4,204 in payments from pharmaceutical and medical device companies, with $157.81 received in 2024. These payments were reported across 241 transactions from 26 companies. The most common payment nature is "Food and Beverage" ($4,204).
As a Medicare-enrolled provider, Quin has provided services to 1,576 Medicare beneficiaries, totaling 3,078 services with total Medicare billing of $199,237. Data is available for 4 years (2020–2023), covering 19 distinct procedure/service records.
Ad
Practice Information
- Specialty Legal Medicine
- Location Peru, IN
- Active Since 07/28/2005
- Last Updated 02/04/2011
- Taxonomy Code 173000000X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1548260714
Products in Payments
- VRAYLAR (Drug) $773.32
- FARXIGA (Drug) $660.85
- UBRELVY (Drug) $306.22
- BREZTRI (Drug) $257.53
- JARDIANCE (Drug) $222.90
- ELIQUIS (Drug) $210.50
- SYNTHROID (Drug) $201.85
- QULIPTA (Drug) $181.85
- NAMZARIC (Drug) $115.84
- Kerendia (Drug) $110.10
- NURTEC ODT (Drug) $98.15
- FREESTYLE LIBRE 3 (Device) $95.28
- STIOLTO (Drug) $66.45
- Dayvigo (Drug) $64.94
- BYSTOLIC (Drug) $62.14
- LINZESS (Drug) $54.87
- MYRBETRIQ (Drug) $52.40
- BELSOMRA (Drug) $50.35
- TRINTELLIX (Drug) $50.15
- HUMALOG (Drug) $47.65
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.